Proline-rich cell-penetrating peptides, particularly the SAP (sweet arrow peptide), (VRLPPP) 3 , have been proposed to be useful intracellular delivery vectors, as a result of their lack of cytotoxicity combined with their capacity to be internalized by cells. A common limitation of the therapeutic use of peptides is metabolic instability. In general, peptides are quickly degraded by proteases upon entry into the bloodstream. The use of all-d-peptide derivatives is emerging as a fruitful strategy to circumvent this degradation problem. In this context, we report on the internalization behaviour, protease-resistance enhancement and self-assembly properties of an all-d version of SAP [(vrlppp) 3 ]. The cellular uptake of (vrlppp) 3 was evaluated in an in vivo assay in mice. Both flow cytometry and confocal laser-scanning microscopy experiments showed that a carboxyfluoresceinated version of the molecule, carboxyfluorescein-(vrlppp) 3 , is internalized rapidly in white blood cells and kidney cells. Significant fluorescence was also detected in other organs such as the spleen and the liver. Finally, the toxicity of (vrlppp) 3 was examined, and no significant differences in the main biochemical parameters nor in weight were detected compared with controls.
Proline-rich peptides in drug delivery: the SAP [sweet arrow peptide, (VRLPPP) 3 ]
High-proline content has been identified as a key signature of several families of CPPs (cell-penetrating peptides) which are structurally diverse: linear peptides [1] [2] [3] [4] [5] , dendrimers [6] and γ -peptides [7, 8] . Among proline-rich linear peptides, the SAP family combines a moderate cellular uptake capacity with a remarkable lack of cytotoxicity [3, [9] [10] [11] . SAP is composed of 50% proline together with three positively charged arginine residues. These residues contain the guanidinium group, which is crucial for cellular uptake in other systems [12] [13] [14] [15] [16] . In solution, SAP adopts an amphipathic PPII (polyproline II) helical structure ( Figure 1 ) and has a strong tendency to selfassemble, forming tubular structures.
Internalization studies of all-d SAP [(vrlppp) 3 ]
Proteolytic stability is a critical requirement for the therapeutic application of CPPs. For this purpose, an enantiomeric version of carboxyfluoresceinated SAP, CF-(vrlppp) 3 , was prepared and evaluated ( Figure 1) . Uptake experiments in HeLa cells using 50 µM peptide solutions in PBS indicated that the all-D CF-SAP was internalized by cells to the same extent as the protease-susceptible parent peptide.
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Figure 1 Structural model of (VRLPPP) 3 and (vrlppp) 3
Structures of both peptides adopting a left-handed [(VRLPPP) 3 ; top] or right-handed [(vrlppp) 3 ; bottom] PPII structure in aqueous solution. Colour code: valine and leucine, yellow; arginine, blue; proline, pink.
Protease-resistance and self-assembly behaviour
The proteolytic stability of all-D SAP was assessed in response to both a highly concentrated trypsin solution and to human serum. Under both conditions, the (vrlppp) 3 peptide was completely stable after more than 48 h of treatment. This behaviour clearly contrasts with that of SAP, which showed rapid degradation when exposed to the same conditions. Both CD and transmission electron microscopy indicated that (vrlppp) 3 forms stable fibrillar structures that are very similar to those reported previously for SAP [17] [18] [19] . 
A preliminary in vivo internalization study
The efficiency observed for in vitro internalization of all-D SAP prompted us to perform an in vivo internalization study in mice [20] . The toxicity of (vrlppp) 3 was evaluated by administration of the peptide (400 nmol in 100 µl of PBS) to Balb/c mice for one week on alternate days by i.p. (intraperitoneal) injection (n = 5), with PBS injected as a control (n = 4). No significant differences in the main blood biochemical parameters nor in weight were detected. For the in vivo internalization studies, a carboxyfluoresceinated version of all-D SAP was used. The uptake of CF-(vrlppp) 3 was monitored in white blood cells and in major organs in mice. The peptide was efficiently taken up in leucocytes, as demonstrated by flow cytometry 1 h after administration. A significant amount of uptake was still detected 5 h after injection, whereas no differences with controls were observed at 24 h (Figure 2) . CLSM (confocal laser-scanning microscopy) was used to study the distribution of CF-(vrlppp) 3 in mouse organs. Confocal images showed a rapid and intense enhancement of fluorescence in kidney sections ( Figure 3A) . Moreover, the fluorescence signal in the kidney sections was still detectable 24 h after i.p. injection. A weaker, but significant, uptake was also observed in spleen and liver sections ( Figure 3B ).
On the basis of these results, we propose that CF-(vrlppp) 3 is a useful tool for intracellular drug delivery.
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